Cancer/testis antigen SSX2 enhances invasiveness in MCF-7 cells by repressing ERá signaling

International Journal of Oncology

Volumn 40, Issue 6, 2012, Pages 1986-1994

  Chen, Ling ^a   Zhou, Wen Bin ^a   Zhao, Yi ^a   Liu, Xiao An ^a   Ding, Qiang ^a   Zha, Xiao Ming ^a   Wang, Shui ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Apoptosis; Breast cancer; Cancer testis antigen; CTA; HOM MEL 40 SSX2; Invasion

Indexed keywords

APOLIPOPROTEIN A1; ARHGDIA PROTEIN; BETA TUBULIN; CANCER TESTIS ANTIGEN; CANCER TESTIS ANTIGEN SSX2; ESTROGEN RECEPTOR ALPHA; HEAT SHOCK PROTEIN 27; LACTATE DEHYDROGENASE; PDIA3 PROTEIN; PEROXIREDOXIN 2; PEROXIREDOXIN 6; PROTEIN; SERUM ALBUMIN; TRANSGELIN; TUBB2C PROTEIN; UNCLASSIFIED DRUG; UVOMORULIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER GROWTH; CANCER INVASION; CARCINOGENICITY; CELL ASSAY; CELL GROWTH; CELL INVASION; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; METASTASIS POTENTIAL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEOMICS; SIGNAL TRANSDUCTION; TRANSWELL INVASION ASSAY;

ANIMALS; ANTIGENS, NEOPLASM; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; ESTROGEN RECEPTOR ALPHA; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; NEOPLASM TRANSPLANTATION; REPRESSOR PROTEINS; SIGNAL TRANSDUCTION; TESTIS; TRANSCRIPTION, GENETIC; TUMOR BURDEN;

EID: 84861771943     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2012.1369     Document Type: Article

References (52)

1. Jemal A, Siegel R, Xu J and Ward E: Cancer statistics, 2010. CA Cancer J Clin 60: 277-300, 2010.
2. Jager E, Jager D and Knuth A: Antigen-specific immunotherapy and cancer vaccines. Int J Cancer 106: 817-820, 2003. (Pubitemid 37071658)
3. Suri A: Cancer testis antigens - their importance in immunotherapy and in the early detection of cancer. Expert Opin Biol Ther 6: 379-389, 2006.
4. Gure AO, Chua R, Williamson B, et al: Cancer-testis genes are coordinately expressed and are markers of poor outcome in non-small cell lung cancer. Clin Cancer Res 11: 8055-8062, 2005. (Pubitemid 41698748)
5. Velazquez EF, Jungbluth AA, Yancovitz M, et al: Expression of the cancer/testis antigen NY-ESO-1 in primary and metastatic malignant melanoma (MM) - correlation with prognostic factors. Cancer Immun 7: 11, 2007.
6. Andrade VC, Vettore AL, Felix RS, et al: Prognostic impact of cancer/testis antigen expression in advanced stage multiple myeloma patients. Cancer Immun 8: 2, 2008.
7. Napoletano C, Bellati F, Tarquini E, et al: MAGE-A and NY-ESO-1 expression in cervical cancer: prognostic factors and effects of chemotherapy. Am J Obstet Gynecol 198: 99 e91-97, 2008.
8. Scanlan MJ, Gure AO, Jungbluth AA, Old LJ and Chen YT: Cancer/testis antigens: an expanding family of targets for cancer immunotherapy. Immunol Rev 188: 22-32, 2002. (Pubitemid 35398862)
9. Silina K, Zayakin P, Kalnina Z, et al: Sperm-associated antigens as targets for cancer immunotherapy: expression pattern and humoral immune response in cancer patients. J Immunother 34: 28-44, 2011.
10. Caballero OL and Chen YT: Cancer/testis (CT) antigens: potential targets for immunotherapy. Cancer Sci 100: 2014-2021, 2009.
11. Curigliano G, Viale G, Ghioni M, et al: Cancer-testis antigen expression in triple-negative breast cancer. Ann Oncol 22: 98-103, 2011.
12. Jager D, Stockert E, Scanlan MJ, et al: Cancer-testis antigens and ING1 tumor suppressor gene product are breast cancer antigens: characterization of tissue-specific ING1 transcripts and a homologue gene. Cancer Res 59: 6197-6204, 1999. (Pubitemid 30035643)
13. Jager E, Karbach J, Gnjatic S, et al: Recombinant vaccinia/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients. Proc Natl Acad Sci USA 103: 14453-14458, 2006. (Pubitemid 44484771)
14. Marchand M, van Baren N, Weynants P, et al: Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int J Cancer 80: 219-230, 1999. (Pubitemid 29001725)
15. Gure AO, Wei IJ, Old LJ and Chen YT: The SSX gene family: characterization of 9 complete genes. Int J Cancer 101: 448-453, 2002.
16. Dubovsky JA and McNeel DG: Inducible expression of a prostate cancer-testis antigen, SSX-2, following treatment with a DNA methylation inhibitor. Prostate 67: 1781-1790, 2007. (Pubitemid 350228730)
17. Naka N, Joyama S, Tsukamoto Y, et al: Quantification of SSX mRNA expression in human bone and soft tissue tumors using nucleic acid sequence-based amplification. J Mol Diagn 7: 187-197, 2005. (Pubitemid 40668301)
18. Tureci O, Sahin U, Schobert I, et al: The SSX-2 gene, which is involved in the t(X;18) translocation of synovial sarcomas, codes for the human tumor antigen HOM-MEL-40. Cancer Res 56: 4766-4772, 1996. (Pubitemid 26338082)
19. Margolin JF, Friedman JR, Meyer WK, Vissing H, Thiesen HJ and Rauscher FJ III: Kruppel-associated boxes are potent transcriptional repression domains. Proc Natl Acad Sci USA 91: 4509-4513, 1994.
20. Witzgall R, O'Leary E, Leaf A, Onaldi D and Bonventre JV: The Kruppel-associated box-A (KRAB-A) domain of zinc finger proteins mediates transcriptional repression. Proc Natl Acad Sci USA 91: 4514-4518, 1994.
21. de Bruijn DR, dos Santos NR, Kater-Baats E, et al: The cancer-related protein SSX2 interacts with the human homologue of a Ras-like GTPase interactor, RAB3IP, and a novel nuclear protein, SSX2IP. Genes Chromosomes Cancer 34: 285-298, 2002. (Pubitemid 34553307)
22. de Bruijn DR, van Dijk AH, Willemse MP and van Kessel AG: The C terminus of the synovial sarcoma-associated SSX proteins interacts with the LIM homeobox protein LHX4. Oncogene 27: 653-662, 2008. (Pubitemid 351158898)
23. Mischo A, Kubuschok B, Ertan K, et al: Prospective study on the expression of cancer testis genes and antibody responses in 100 consecutive patients with primary breast cancer. Int J Cancer 118: 696-703, 2006. (Pubitemid 43076020)
24. Stockert E, Jager E, Chen YT, et al: A survey of the humoral immune response of cancer patients to a panel of human tumor antigens. J Exp Med 187: 1349-1354, 1998. (Pubitemid 28189124)
25. Smith HA and McNeel DG: The SSX family of cancer-testis antigens as target proteins for tumor therapy. Clin Dev Immunol 2010: 150591, 2010.
26. Cronwright G, Le Blanc K, Gotherstrom C, Darcy P, Ehnman M and Brodin B: Cancer/testis antigen expression in human mesechymal stem cells: down-regulation of SSX impairs cell migration and matrix metalloproteinase 2 expression. Cancer Res 65: 2207-2215, 2005. (Pubitemid 40490129)
27. Ghafouri-Fard S and Modarressi MH: Cancer-testis antigens: potential targets for cancer immunotherapy. Arch Iran Med 12: 395-404, 2009.
28. Zhai YF, Esselman WJ, Oakley CS, Chang CC and Welsch CW: Growth of MCF-7 human breast carcinoma in severe combined immunodeficient mice: growth suppression by recombinant interleukin-2 treatment and role of lymphokine-activated killer cells. Cancer Immunol Immunother 35: 237-245, 1992.
29. Kubota T, Yamaguchi H, Watanabe M, et al: Growth of human tumor xenografts in nude mice and mice with severe combined immunodeficiency (SCID). Surg Today 23: 375-377, 1993. (Pubitemid 23107579)
30. Ye Y, Xiao Y, Wang W, Yearsley K, Gao JX and Barsky SH: ERalpha suppresses slug expression directly by transcriptional repression. Biochem J 416: 179-187, 2008.
31. Thiery JP and Sleeman JP: Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol 7: 131-142, 2006. (Pubitemid 43278296)
32. Kang Y and Massague J: Epithelial-mesenchymal transitions: twist in development and metastasis. Cell 118: 277-279, 2004. (Pubitemid 39061108)
33. Ye Y, Xiao Y, Wang W, et al: ERalpha signaling through slug regulates E-cadherin and EMT. Oncogene 29: 1451-1462, 2010.
34. Lawson D, Harrison M and Shapland C: Fibroblast transgelin and smooth muscle SM22alpha are the same protein, the expression of which is down-regulated in many cell lines. Cell Motil Cytoskeleton 38: 250-257, 1997. (Pubitemid 27484089)
35. Shields JM, Rogers-Graham K and Der CJ: Loss of transgelin in breast and colon tumors and in RIE-1 cells by Ras deregulation of gene expression through Raf-independent pathways. J Biol Chem 277: 9790-9799, 2002. (Pubitemid 34968082)
36. Shalli K, Brown I, Heys SD and Schofield AC: Alterations of beta-tubulin isotypes in breast cancer cells resistant to docetaxel. FASEB J 19: 1299-1301, 2005. (Pubitemid 41113729)
37. El Marzouk S, Schultz-Norton JR, Likhite VS, McLeod IX, Yates JR and Nardulli AM: Rho GDP dissociation inhibitor alpha interacts with estrogen receptor alpha and influences estrogen responsiveness. J Mol Endocrinol 39: 249-259, 2007. (Pubitemid 350047646)
38. O'Callaghan-Sunol C, Gabai VL and Sherman MY: Hsp27 modulates p53 signaling and suppresses cellular senescence. Cancer Res 67: 11779-11788, 2007.
39. Gimona M, Buccione R, Courtneidge SA and Linder S: Assembly and biological role of podosomes and invadopodia. Curr Opin Cell Biol 20: 235-241, 2008.
40. Boulter E, Garcia-Mata R, Guilluy C, et al: Regulation of Rho GTPase crosstalk, degradation and activity by RhoGDI1. Nat Cell Biol 12: 477-483, 2010.
41. Razandi M, Pedram A and Levin ER: Heat shock protein 27 is required for sex steroid receptor trafficking to and functioning at the plasma membrane. Mol Cell Biol 30: 3249-3261, 2010.
42. Dos Santos Hidalgo G, Meola J, Rosa ESJC, Paro de Paz CC and Ferriani RA: TAGLN expression is deregulated in endometriosis and may be involved in cell invasion, migration, and differentiation. Fertil Steril 96: 700-703, 2011.
43. Russell C: The role of albumin-bound Paclitaxel in metastatic breast cancer. Clin Adv Hematol Oncol 9: 469-471, 2011.
44. Lis CG, Grutsch JF, Vashi PG and Lammersfeld CA: Is serum albumin an independent predictor of survival in patients with breast cancer? J Parenter Enteral Nutr 27: 10-15, 2003. (Pubitemid 36109150)
45. Ivanenkov VV, Dimlich RV and Jamieson GA Jr: Interaction of S100a0 protein with the actin capping protein, CapZ: characterization of a putative S100a0 binding site in CapZ alpha-subunit. Biochem Biophys Res Commun 221: 46-50, 1996.
46. Soiland H, Soreide K, Janssen EA, Korner H, Baak JP and Soreide JA: Emerging concepts of apolipoprotein D with possible implications for breast cancer. Cell Oncol 29: 195-209, 2007. (Pubitemid 46855702)
47. Chang XZ, Li DQ, Hou YF, et al: Identification of the functional role of peroxiredoxin 6 in the progression of breast cancer. Breast Cancer Res 9: R76, 2007.
48. Lim FL, Soulez M, Koczan D, Thiesen HJ and Knight JC: A KRAB-related domain and a novel transcription repression domain in proteins encoded by SSX genes that are disrupted in human sarcomas. Oncogene 17: 2013-2018, 1998. (Pubitemid 28488471)
49. Ma ZQ, Tsai MJ and Tsai SY: Suppression of gene expression by tethering KRAB domain to promoter of ER target genes. J Steroid Biochem Mol Biol 69: 155-163, 1999.
50. Chen H, Hewison M and Adams JS: Control of estradiol-directed gene transactivation by an intracellular estrogen-binding protein and an estrogen response element-binding protein. Mol Endocrinol 22: 559-569, 2008. (Pubitemid 351397785)
51. Kennedy MJ, Donehower RC and Rowinsky EK: Treatment of metastatic breast cancer with combination paclitaxel/cyclophosphamide. Semin Oncol 22: 23-27, 1995.
52. Davidson NG: Single-agent paclitaxel at first relapse following adjuvant chemotherapy for breast cancer. Semin Oncol 22: 2-6, 1995.